Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 371 | 5,581 | 236 | 267 | 1,327 |
| Gross Profit | 371 | 5,581 | 236 | 267 | 1,327 |
| Operating Expenses | 52,926 | 34,920 | 36,566 | 33,448 | 26,560 |
| Operating Income | -52,555 | -29,340 | -36,329 | -33,181 | -25,232 |
| Interest Expense | 513 | 1,068 | 1,984 | 2,847 | 2,804 |
| Other Income | -900 | 7,992 | 59,244 | -92,243 | -5,099 |
| Pre-tax Income | -53,968 | -22,415 | 20,931 | -128,271 | -33,135 |
| Income Tax | N/A | 1,923 | 1,760 | 902 | N/A |
| Net Income Continuous | -53,968 | -24,338 | 19,171 | -129,173 | -33,135 |
| Minority Interests | N/A | N/A | N/A | -469 | -594 |
| Net Income | $-53,968 | $-24,338 | $19,171 | $-128,703 | $-32,541 |
| EPS Basic Total Ops | -3.24 | -1.20 | 1.44 | -9.96 | -3.12 |
| EPS Basic Continuous Ops | -3.20 | -1.21 | 1.39 | -9.95 | -3.19 |
| EPS Diluted Total Ops | -3.24 | -1.08 | 1.32 | -9.96 | -3.12 |
| EPS Diluted Continuous Ops | -3.20 | -1.14 | 1.32 | -9.95 | -3.19 |
| EBITDA(a) | $-51,479 | $-27,446 | $-35,477 | $-32,517 | $-24,014 |